Institut Català de la Salut
[Pijnenburg L, Arnaud L] Service de rhumatologie, Centre de Référence des Maladies Auto-immunes Systémiques Rares Est Sud-Ouest Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France. [Giannini M] Service de rhumatologie, Centre de Référence des Maladies Auto-immunes Systémiques Rares Est Sud-Ouest Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France. Exploration fonctionnelle musculaire, Service de Physiologie Explorations Fonctionnelles Musculaires, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France. [Bouchard-Marmen M] Division of Rheumatology, CHU de Quebec-Universite Laval, Quebec, Quebec, Canada. [Barsotti S] Department of Rheumatology and Clinical Immunology Unit, University of Pisa, Pisa, Italy. [Bellando-Randone S] Department of Experimental and Clinical Medicine, Universitaria Careggi, Azienda Ospedaliera, Florence, Italy. [Selva-O'Callaghan A] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2023-09-19T08:31:24Z
2023-09-19T08:31:24Z
2023-08
Dermatomyositis; Polymyositis; Systemic sclerosis
Dermatomiositis; Polimiositis; Esclerosis sistémica
Dermatomiositis; Polimiositis; Esclerosi sistèmica
Background Some myopathies can lead to dropped head or bent spine syndrome (DH/BS). The significance of this symptom has not been studied in inflammatory myopathies (IM). Objectives To assess the significance of DH/BS in patients with IM. Methods Practitioners from five IM networks were invited to report patients with IM suffering from DH/BS (without other known cause than IM). IM patients without DH/BS, randomly selected in each participating centre, were included as controls at a ratio of 2 to 1. Results 49 DH/BS-IM patients (DH: 57.1%, BS: 42.9%) were compared with 98 control-IM patients. DH/BS-IM patients were older (65 years vs 53 years, p<0.0001) and the diagnosis of IM was delayed (6 months vs 3 months, p=0.009). Weakness prevailing in the upper limbs (42.9% vs 15.3%), dysphagia (57.1% vs 25.5%), muscle atrophy (65.3% vs 34.7%), weight loss (61.2% vs 23.5%) and loss of the ability to walk (24.5% vs 5.1%) were hallmarks of DH/BS-IM (p≤0.0005), for which the patients more frequently received intravenous immunoglobulins (65.3% vs 34.7%, p=0.0004). Moreover, DH/BS-IM patients frequently featured signs and/or complications of systemic sclerosis (SSc), fulfilling the American College of Rheumatology/European Alliance of Associations for Rheumatology criteria for this disease in 40.8% of the cases (vs 5.1%, p<0.0001). Distribution of the myopathy, its severity and its association with SSc were independently associated with DH/BS (p<0.05). Mortality was higher in the DH/BS-IM patients and loss of walking ability was independently associated with survival (p<0.05). Conclusion In IM patients, DH/BS is a marker of severity and is associated with SSc (scleromyositis).
Article
Published version
English
Músculs - Malalties - Complicacions; Esclerosi sistemàtica progressiva; DISEASES::Musculoskeletal Diseases::Muscular Diseases::Myositis; Other subheadings::Other subheadings::Other subheadings::/complications; DISEASES::Skin and Connective Tissue Diseases::Connective Tissue Diseases::Scleroderma, Systemic; DISEASES::Musculoskeletal Diseases::Muscular Diseases::Muscle Weakness; ENFERMEDADES::enfermedades musculoesqueléticas::enfermedades musculares::miositis; Otros calificadores::Otros calificadores::Otros calificadores::/complicaciones; ENFERMEDADES::enfermedades de la piel y tejido conjuntivo::enfermedades del tejido conjuntivo::esclerodermia sistémica; ENFERMEDADES::enfermedades musculoesqueléticas::enfermedades musculares::debilidad muscular
BMJ
RMD Open;9(3)
http://dx.doi.org/10.1136/rmdopen-2023-003081
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
Articles científics - HVH [3440]